Pegylated synthetic human c-peptide
Also known as: C-peptide (pegylated), Long-acting C-peptide, PEG-C-peptide, PEG‑C‑peptide, Pegylated C‑peptide, Synthetic human C-peptide PEG conjugate
Source Pegylated synthetic human c-peptide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
A 31‑aa human C‑peptide chemically linked to polyethylene glycol to improve stability and half‑life; investigated for diabetic neuropathy, nephropathy and microvascular complications.
Mechanism of Action
Pegylated C‑peptide binds to a yet‑characterized cell‑surface receptor, enhancing microvascular blood flow, reducing inflammation and apoptosis in diabetic tissues; pegylation extends plasma half‑life.
Routes of Administration
Goals & Uses
- Improved pharmacokinetics over native C-peptidePharmacokinetic OptimizationModerate
- Diabetic nephropathyRenalLow
- Diabetic retinopathy preventionOphthalmological / Diabetic ComplicationLow
- Diabetic peripheral neuropathy improvementNeuroprotection / Nerve FunctionModerate
- Diabetic peripheral neuropathyNeuropathyModerate
- Diabetic nephropathy attenuationRenal ProtectionModerate
- Microvascular function restorationVascular / Diabetic ComplicationModerate
Contraindications
- Known hypersensitivity to PEGAllergyHigh
- Hypersensitivity to C-peptide or PEG excipientsAllergic / ImmunologicalHigh
- Severe renal impairmentOrganModerateKidney function concerns
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Type 2 diabetes with endogenous C-peptide productionEndocrineModerate
Adverse Effects
- Anti-PEG antibody formationImmunologicalUncommon
- HypoglycemiaMetabolicRareAbnormally low blood glucose
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Renal PEG accumulationRenalRare
- Mild flu-like symptomsSystemicUncommon
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- Anticoagulants (e.g., warfarin)Moderate
- InsulinModerateMay increase risk of low blood sugar
- ACE inhibitors / ARBsLow
- Other PEGylated biologicsModerate
Population Constraints
- Pediatric patients (<12 yr)AgeRelative
- Pediatric populationAgeRelative
- Elderly patients (>75 years)AgeRelative
- Patients with prior severe PEG hypersensitivityImmunologicalAbsolute
- Type 1 diabetes mellitus (C-peptide deficient)Endocrine / Target PopulationAbsolute
Regulatory Status
- European UnionInvestigationalClinical trial authorization granted in several member states.
- United StatesInvestigationalUnder IND for diabetic neuropathy; not FDA‑approved.
- United KingdomInvestigationalNot approved by MHRA; research use only
No approved therapeutic use in any major jurisdiction. Investigational compound in early-phase clinical research. Not approved by FDA, EMA, or MHRA. Some formulations studied under IND or equivalent regulatory frameworks.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Pegylated synthetic human c-peptide?
A 31‑aa human C‑peptide chemically linked to polyethylene glycol to improve stability and half‑life; investigated for diabetic neuropathy, nephropathy and microvascular complications.
What is Pegylated synthetic human c-peptide used for?
Pegylated synthetic human c-peptide is educationally associated with: Improved pharmacokinetics over native C-peptide, Diabetic nephropathy, Diabetic retinopathy prevention, Diabetic peripheral neuropathy improvement, Diabetic peripheral neuropathy, Diabetic nephropathy attenuation, Microvascular function restoration. Educational only — not medical advice.
How is Pegylated synthetic human c-peptide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Pegylated synthetic human c-peptide?
Reported adverse effects include: Anti-PEG antibody formation, Hypoglycemia, Injection site reactions, Headache, Renal PEG accumulation, Mild flu-like symptoms, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Pegylated synthetic human c-peptide?
Recorded contraindications: Known hypersensitivity to PEG, Hypersensitivity to C-peptide or PEG excipients, Severe renal impairment, Pregnancy, Type 2 diabetes with endogenous C-peptide production. Consult a qualified clinician before use.